万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://www.springer.com/journal/280/
3、投稿网址：https://www.editorialmanager.com/ccap
4、官网邮箱：
ccap.unsolicitedreviews@gmail.com（编辑）
（更多相关咨询邮箱如下）
5、期刊刊期：月刊，一年出版12期。
2022年1月11日星期二
期刊相关咨询邮箱【官网信息】
Contact the journal
Submission-related enquiries
Queries about submission issues, peer review process, or the status of your manuscript should be sent to Janani Sargunam (Janani.Sargunam@springernature.com).
Production-related enquiries
Queries about accepted manuscripts in production or post-publication corrections should be sent to Remya Ganesan (Remya.Ganesan@springer.com).
Rights and Permissions enquiries
For permission requests to reuse or reprint content, please follow the link ‘Rights and permissions’ on the relevant article page. For other queries, contact journalpermissions@springernature.com.
Publication-related enquiries
Queries related to journal publishing should be sent to Mehak Massand (mehak.massand@springer.com).
投稿须知【官网信息】
Cancer Chemotherapy and Pharmacology
Submission guidelines
Instructions for Authors
Types of papers
CCP will consider for publication the following articles: The word limits shown are guidelines only.
Original articles - word limit 5000 words, 45 references, 6 figures/tables
Short scientific communication - 2500 words, 20 references, 2 figures/tables
Review articles: word limit 10000 words, 100 references, 10 figures
Position Papers
Consensus Statements
Letters to editor: 500 words
Editorials
Unsolicited Therapeutics Reviews
Presubmission Inquiry (for Unsolicited Therapeutics Reviews only):
Please submit your inquiry to the Editor: ccap.unsolicitedreviews@gmail.com, with the following information:
1. - A brief outline that includes pertinent details of the review, explaining the needs of such a contribution to the field.
2. - A list of the author publications in the last 10 years. For multi-authored papers, only the corresponding author needs to submit the list.
Should the Editor approve the submission, the author will be notified to submit online via: https://www.editorialmanager.com/ccap/ and select “Unsolicited Therapeutics Review” as the article type.
Please communicate other queries and questions that are not regarding a specific therapeutics unsolicited review article to the contacts listed on the journal home page (https://www.springer.com/medicine/oncology/journal/280/); only pre-submission inquiries that contain all of the above required details will be acknowledged at this email address and be able to proceed through the submission process.
CCP does not consider:
*Studies that describe the effects of biological extracts, i.e. normally natural products, where the extracts is not a single chemical species with a fully defined chemical structure.
*Studies that describe data generated using a single cell line or cell line pair, or tumour. Such studies should be repeated in a panel of, preferably, human tumour cell lines to demonstrate the generality of the results obtained, and where appropriate studies should be extended to investigate the putative molecular target of the agent(s) and the relationship between drug-target interaction and phenotypic effects such as cell growth inhibition or apoptosis induction. For in vivo studies, pharmacokinetic data should be included to confirm that drug levels commensurate with activity in vitro can be achieved and maintained in vivo at tolerated doses, and that in combination studies there are no pharmacokinetic interactions.
*Studies that describe case reports, unless novel primary pharmacokinetic and/or pharmacodynamic data are presented. CCP does not consider standard clinical case reports. Springer has recently launched the Journal of Medical Case Reports: http://www.springer.com/medicine/journal/13256?changeHeader and you may wish to consider submitting you report to this journal.
*Studies that describe the retrospective audit of clinical data, especially when the data are from a single institution, unless the disease setting is one in which clinical trials are not ethically or technically feasible. CCP focuses on the publication of Phase 0/I/II and III trials, particularly those that include prognostic, predictive, pharmacological (PK and PD) and surrogate response biomarker investigations.
*Meta-analyses or systematic reviews unless they relate directly to pharmacokinetic or mechanistic pharmacodynamic data.
CCP views with lower priority Phase I or Phase II studies which deal with small numbers of subjects, and contain clinical observations only without pharmacologic or pharmacodynamic observations. Such studies may not be sent out for review unless the authors present a compelling rationale for the importance of the information.
PRISMA guidelines
Guidelines to Authors
CCAP does not consider reports of microRNAs or long noncoding RNAs that modulate the biologic behavior of a cell line or cell line pair, unless the formulation of the RNA could be administered to an animal model, and in that event the observation should be accompanied with experiments in an in vivo model supporting the new construct as a potential chemotherapeutic agent. Studies without a practical formulation and no effect in an in vivo model may be considered if compelling relevance of the microRNA or long noncoding RNA to the action of a clinically approved chemotherapeutic agent is apparent.
……
更多详情：
https://www.springer.com/journal/280/submission-guidelines
